FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024118914> ?p ?o ?g. }

• W2024118914 endingPage "49" @default.
• W2024118914 startingPage "44" @default.
• W2024118914 abstract "In primary minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS), increased lymphocyte reactivity to renal antigens has been defined. Soluble HLA class I antigen (sHLA-I) is actively secreted by T and B lymphocytes when they are stimulated by mitogens, antigens and lymphokines. To determine if serum and urine sHLA-I levels could predict steroid response in patients with MCD and differentiate those from FSGS, we have investigated 45 healthy controls, biopsy-proven 17 patients with MCD (edema and 24-hour urine protein > 3.5 g/day), 8 patients with FSGS (24-hour urine protein > 1 g/day) and 10 patients with membranous nephropathy (MGN) (24-hour urine protein > 1 g/day). Before and after prednisone therapy (1 mg/kg/day or 2 mg/kg/EOD for 8 weeks), the levels of serum and urinary sHLA-I were measured by ELISA (sHLA-STAT; Sangstat Co., Calif., USA). After 8 weeks of treatment, 10 patients with MCD were responders (MCD-CR) while the other 7 patients with MCD were nonresponders (MCD-NR). Three of 7 patients with MCD-NR were re-biopsied and finally diagnosed as FSGS. They were included in the data of patients with FSGS. In healthy controls, serum sHLA-I was detected (415 +/- 256 ng/ml), but urinary sHLA-I was not. At entry, there were no differences in age, sex, serum Cr and 24-hour urine protein among the patients with MCD-CR, MCD-NR and FSGS, but serum albumin was significantly elevated in patients with FSGS and MGN (p < 0.05). Serum sHLA-I levels were notably elevated in MCD-CR (1,040 +/- 1,066 ng/ ml), in MCD-NR (668 +/- 315 ng/ml) and in FSGS (713 +/- 790 ng/ml), but not in patients with MGN (444 +/- 86 ng/ml) when compared with controls (p < 0.05). On the other hand, urinary sHLA-I levels in MCD-NR (541 +/- 239 ng/mg Cr) and in FSGS (457 +/- 239 ng/mg Cr) were significantly higher than those in MGN (125 +/- 28 ng/mg Cr) and in MCD-CR(100 +/- 42 ng/mg Cr, p < 0.05) and these substantial differences were maintained for 8 weeks. In all patients, serum and urinary sHLA-I levels were not reduced during 8 weeks of steroid therapy. We conclude that elevated serum and urinary sHLA-I levels reflect increased cellular immune response and disease activity in patients with MCD and FSGS. In patients with MCD, urinary sHLA-I may be an easily measurable indicator of predicting steroid response, while MCD-NR with high urinary sHLA-I levels might be re-evaluated for the possibility of FSGS." @default.
• W2024118914 created "2016-06-24" @default.
• W2024118914 creator A5008711081 @default.
• W2024118914 creator A5011073372 @default.
• W2024118914 creator A5035228519 @default.
• W2024118914 creator A5046255806 @default.
• W2024118914 creator A5052100533 @default.
• W2024118914 creator A5065254353 @default.
• W2024118914 creator A5071322443 @default.
• W2024118914 creator A5072255737 @default.
• W2024118914 creator A5080224581 @default.
• W2024118914 date "1998-01-01" @default.
• W2024118914 modified "2023-10-13" @default.
• W2024118914 title "Urinary Soluble HLA Class I Antigen in Patients with Minimal Change Disease: A Predictor of Steroid Response" @default.
• W2024118914 cites W1934893658 @default.
• W2024118914 cites W1974212716 @default.
• W2024118914 cites W1991147271 @default.
• W2024118914 cites W1995044367 @default.
• W2024118914 cites W2017263183 @default.
• W2024118914 cites W2021578270 @default.
• W2024118914 cites W2026075476 @default.
• W2024118914 cites W2026303060 @default.
• W2024118914 cites W2027957168 @default.
• W2024118914 cites W2053563492 @default.
• W2024118914 cites W2057619478 @default.
• W2024118914 cites W2070846129 @default.
• W2024118914 cites W2074538889 @default.
• W2024118914 cites W2090627576 @default.
• W2024118914 cites W2091614482 @default.
• W2024118914 cites W2091828934 @default.
• W2024118914 cites W2092799874 @default.
• W2024118914 cites W2136154268 @default.
• W2024118914 cites W2151098851 @default.
• W2024118914 cites W2173936036 @default.
• W2024118914 cites W2174769340 @default.
• W2024118914 cites W2413331954 @default.
• W2024118914 cites W2414343988 @default.
• W2024118914 cites W2416844367 @default.
• W2024118914 cites W96995753 @default.
• W2024118914 doi "https://doi.org/10.1159/000044990" @default.
• W2024118914 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9609461" @default.
• W2024118914 hasPublicationYear "1998" @default.
• W2024118914 type Work @default.
• W2024118914 sameAs 2024118914 @default.
• W2024118914 citedByCount "2" @default.
• W2024118914 countsByYear W20241189142014 @default.
• W2024118914 crossrefType "journal-article" @default.
• W2024118914 hasAuthorship W2024118914A5008711081 @default.
• W2024118914 hasAuthorship W2024118914A5011073372 @default.
• W2024118914 hasAuthorship W2024118914A5035228519 @default.
• W2024118914 hasAuthorship W2024118914A5046255806 @default.
• W2024118914 hasAuthorship W2024118914A5052100533 @default.
• W2024118914 hasAuthorship W2024118914A5065254353 @default.
• W2024118914 hasAuthorship W2024118914A5071322443 @default.
• W2024118914 hasAuthorship W2024118914A5072255737 @default.
• W2024118914 hasAuthorship W2024118914A5080224581 @default.
• W2024118914 hasConcept C126322002 @default.
• W2024118914 hasConcept C134018914 @default.
• W2024118914 hasConcept C147483822 @default.
• W2024118914 hasConcept C203014093 @default.
• W2024118914 hasConcept C2775946357 @default.
• W2024118914 hasConcept C2777747828 @default.
• W2024118914 hasConcept C2778415529 @default.
• W2024118914 hasConcept C2778720950 @default.
• W2024118914 hasConcept C2778930706 @default.
• W2024118914 hasConcept C2779561371 @default.
• W2024118914 hasConcept C2780026642 @default.
• W2024118914 hasConcept C2780091579 @default.
• W2024118914 hasConcept C71924100 @default.
• W2024118914 hasConcept C77411442 @default.
• W2024118914 hasConcept C90924648 @default.
• W2024118914 hasConceptScore W2024118914C126322002 @default.
• W2024118914 hasConceptScore W2024118914C134018914 @default.
• W2024118914 hasConceptScore W2024118914C147483822 @default.
• W2024118914 hasConceptScore W2024118914C203014093 @default.
• W2024118914 hasConceptScore W2024118914C2775946357 @default.
• W2024118914 hasConceptScore W2024118914C2777747828 @default.
• W2024118914 hasConceptScore W2024118914C2778415529 @default.
• W2024118914 hasConceptScore W2024118914C2778720950 @default.
• W2024118914 hasConceptScore W2024118914C2778930706 @default.
• W2024118914 hasConceptScore W2024118914C2779561371 @default.
• W2024118914 hasConceptScore W2024118914C2780026642 @default.
• W2024118914 hasConceptScore W2024118914C2780091579 @default.
• W2024118914 hasConceptScore W2024118914C71924100 @default.
• W2024118914 hasConceptScore W2024118914C77411442 @default.
• W2024118914 hasConceptScore W2024118914C90924648 @default.
• W2024118914 hasIssue "1" @default.
• W2024118914 hasLocation W20241189141 @default.
• W2024118914 hasLocation W20241189142 @default.
• W2024118914 hasOpenAccess W2024118914 @default.
• W2024118914 hasPrimaryLocation W20241189141 @default.
• W2024118914 hasRelatedWork W1939640568 @default.
• W2024118914 hasRelatedWork W2007084118 @default.
• W2024118914 hasRelatedWork W2042172609 @default.
• W2024118914 hasRelatedWork W2058621176 @default.
• W2024118914 hasRelatedWork W2409021282 @default.
• W2024118914 hasRelatedWork W2564648259 @default.
• W2024118914 hasRelatedWork W2609120769 @default.

• next